Company: NYXH
Filing Date: 2025-03-20
Form Type: 20-F
Source: 0001410578-25-000398
Chunk: 12

Company: Nyxoah SA
Filing Date: 2025-03-20
Form: 20-F
Item: Item 5
Chunk 12
---
 € 0.7 million, or 130%, from €0.5 million for the year ended December 31, 2022, to €1.2 million for the year ended December 31, 2023. The increase is mainly due to the start of a new ERP implementation.
Operating Loss
The increase of operating loss from €32.5 million in 2022 to €45.1 million in 2023, or a change of €12.6 million, was mainly due to increases of activities in all departments. We are currently conducting three clinical trials to continue gathering clinical data and obtain regulatory approvals. During first quarter of 2023 enrollment in the Dream trial designed to support marketing authorization in the United States was completed. We continue to enroll additional patients in EliSA, and ACCCESS studies. In line with its strategy, we continue to invest in research and development to improve and develop the next generation of the Genio system and prepare for scaling-up of production capacities.
Recently Issued Accounting Pronouncements
We applied for the first-time certain interpretations and amendments, which are effective for annual periods beginning on or before January 1, 2024. The new standards and amendments that apply for the first time in 2024 are not expected to have a material impact on our financial position, results of operations or cash flows and are described in Note 2.2 to our consolidated financial statements found elsewhere in this Annual Report.
Emerging Growth Company and Foreign Private Issuer Status
Emerging Growth Company Status
As a company with an annual revenue under $1.235 billion, we qualify as an “emerging growth company” as defined in the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies.

107

These provisions include:

●   the ability to present only two years of audited financial statements in addition to any required interim financial statements and correspondingly reduced disclosure in management’s discussion and analysis of financial condition and results of operations in this Annual Report;
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   exemption from the auditor attestation requirement of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, in the assessment of our internal controls over financial reporting; and
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

●   to the extent that we no longer qualify as a foreign private issuer, (i) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (